Year: 2015
Type: review
Abstract: Parkinson disease (PD) is a progressive neurodegenerative disease that is associated with substantial morbidity and early mortality. Disease-related costs exceed $10 billion, not including medications, out-of-pocket expenses, or societal costs. Symptomatic treatment with levodopa, which has been available for over 30 years, and advanced therapies such as deep brain stimulation improve outcomes. Yet most new medications for PD provide a therapeutic benefit that is relatively modest compared to the benefits from levodopa. Despite dozens of neuroprotective clinical trials, there are no medications proven to slow the progression of the disease. Given these limitations, we provide evidence of the potential public health impact of a research agenda that emphasizes identification of risk factors to reduce disease burden through exposure mitigation. In addition, we emphasize health care policy that focuses on increasing health care expenditures for neurologic evaluation and management services to increase access to specialists to improve disease outcomes and reduce costs through better disease management.
Source: Neurology
Authors: Brad A. Racette, Allison W. Willis
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Michael J. Fox Foundation for Parkinson's Research, Pfizer, Teva Pharmaceutical Industries, American Parkinson Disease Association, University of Pennsylvania, Adamas Pharmaceuticals, Eisai, Merz Pharmaceuticals, National Institutes of Health, Allergan, Civitas Therapeutics, National Institute of Neurological Disorders and Stroke, National Institute of Environmental Health Sciences, National Center for Research Resources, National Center for Advancing Translational Sciences
Awards: Parkinson Disease Disparities and Outcomes, Risk of Parkinson Disease Associated with Solvent Exposures in Finland, Washington University Institute of Clinical and Translational Sciences, Effects-Related Biomarkers of Environmental Neurotoxic Exposures, G4467312596, Washington University Institute of Clinical and Translational Sciences, Washington University Institute of Clinical and Translational Sciences (KL2), Imaging Biomarkers of Neurotoxicity in Welders, Washington University Institute of Clinical and Translational Sciences (UL1), Epidemiology and Biomarkers of Parkinsonism in Welders, G9000181647, G9000271159
OpenAlex ID: W1559000406